Estrella Ebitda from 2010 to 2024

ESLAW Stock   0.09  0  3.53%   
Estrella Immunopharma EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA is likely to outpace its year average in 2024. During the period from 2010 to 2024, Estrella Immunopharma EBITDA regression line of quarterly data had r-squared of  0.33 and coefficient of variation of (144.53). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-7.3 M
Current Value
-6.9 M
Quarterly Volatility
2.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 1.7 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.39. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Estrella Immunopharma's Ebitda Growth Pattern

Below is the plot of the Ebitda of Estrella Immunopharma over the last few years. It is Estrella Immunopharma's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

Estrella Ebitda Regression Statistics

Arithmetic Mean(1,565,899)
Coefficient Of Variation(144.53)
Mean Deviation1,483,052
Median(733,693)
Standard Deviation2,263,138
Sample Variance5.1T
Range7.1M
R-Value(0.58)
Mean Square Error3.7T
R-Squared0.33
Significance0.02
Slope(292,499)
Total Sum of Squares71.7T

Estrella Ebitda History

2024-6.9 M
2023-7.3 M
2022-915.5 K
2021-247.7 K

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-7.3 M-6.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.